Mr. Terry Howlett reports
OVATION SCIENCE INC. ANNOUNCES ADOPTION OF SEMI-ANNUAL FINANCIAL REPORTING
Ovation Science Inc. will adopt semi-annual financial reporting under the
Canadian Securities Administrators' semi-annual reporting pilot program, in reliance on Coordinated
Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers.
This news release is being filed pursuant to Coordinated Blanket Order 51-933, Exemptions to Permit
Semi-Annual Reporting for Certain Venture Issuers.
The initial interim period for which the company does not intend to file an interim financial report and related
management's discussion and analysis (MD&A) is the three- and nine-month periods ended Sept. 30, 2026.
The company will continue to file audited annual financial statements and related MD&A, as well as interim
financial reports and related MD&A for the six-month period ending June 30 of each financial year. The
company will not file interim financial reports or related MD&A for the three- and nine-month periods of its
financial year while it relies on the blanket order. The company remains subject to all other continuous
disclosure obligations under applicable securities laws and the policies of the Canadian Securities
Exchange, including timely disclosure and material change reporting requirements. If the company ceases
to rely on the blanket order, it will issue a news release indicating the next interim period for which it will
file an interim financial report and related MD&A.
"Moving to semi-annual reporting is expected to allow Ovation to reduce the cost and administrative burden
of quarterly reporting and focus our resources on commercial growth, while continuing to keep our
shareholders informed through our ongoing disclosure," said Terry Howlett, chief executive officer.
About Ovation Science Inc.
Ovation Science, together with its wholly owned subsidiary, Ovation Science USA Inc., is a research
and development company that develops topical and transdermal CBD/THC (cannabidiol/tetrahydrocannabinol) and other cannabinoid
products that are out-licensed and also distributed under Ovation's own brands, all powered by its
patented Invisicare skin delivery technology. Invisicare enhances the delivery of ingredients to and
through the skin, and is protected by patents and proprietary formulations. With over 20 years of
pharmaceutical drug delivery experience, Ovation's management and science team have created a unique
pipeline of proprietary medical/wellness topical and transdermal products along with a line of anti-aging/beauty formulas. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along
with revenue from its own product sales. Ovation has offices in Vancouver, Canada, and Las Vegas, U.S.
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.